EDI-M409

EDI-M409 is a preclinical-stage small molecule therapeutic being developed by the Empire Discovery Institute (EDI). It is designed to modulate a key protein within the nonsense-mediated decay (NMD) pathway, a cellular surveillance mechanism that identifies and degrades mRNA transcripts containing premature termination codons (PTCs). In genetic conditions such as Fragile X Syndrome, NMD can exacerbate the disease phenotype by eliminating potentially functional, albeit truncated, proteins. By targeting the NMD machinery, EDI-M409 aims to stabilize these transcripts and restore protein expression levels, offering a potential disease-modifying approach for Fragile X Syndrome and other NMD-related genetic disorders.